Overview

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

This study is designed to compare the efficacy and safety of higher doses of Rituxan with a regimen combining standard doses of Rituxan + CVP in patients with chronic ITP who did not respond to or relapsed after standard doses of Rituxan. Patients eligible for this protocol will be stratified into two subgroups according to their initial response to Rituxan.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborators:

Biogen
Genentech, Inc.

Treatments:

Cyclophosphamide
Prednisone
Rituximab
Vincristine